---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-000758"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:04:04.974980+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway

## Summary
- Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.
- Cash and equivalents $139.4M at Mar 31, 2024; estimated ~4-year runway at current burn rate.
- R&D expenses $9.7M, G&A $2.8M; no revenue as clinical-stage biopharma.
- Marketing Authorisation application for blarcamesine (Alzheimer's) submitted to EMA; FDA guidance supports single cognitive endpoint.
- First cohort fully enrolled in ANAVEX3-71 Phase 2 schizophrenia trial; Phase 2b/3 Alzheimer's data to be published.

## SEC filing metadata
- accession: 0001731122-24-000758
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/0001731122-24-000758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/e5655_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-000758
- JSON: https://secwatch.observer/filing/0001731122-24-000758.json
- Plain text: https://secwatch.observer/filing/0001731122-24-000758.txt

## Key facts
- Earnings Releases
  ANAVEX LIFE SCIENCES CORP. reported financial results for its fiscal quarter ended March 31, 2024.
  - Period: its fiscal quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Anavex Life Sciences Corp. (the “ Company ”) issued a press release reporting financial results for its fiscal quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/0001731122-24-000758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.